Edges in Network
| Network | GSE16446_egf1520 - GSE16446 - SiGN-BN HC+Bootstrap |
| Network Description | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| Node | SLC16A6 |
| Upstream (Parents) |
|---|
| (<<) ATP2B1 → SLC16A6 |
| (<<) BLNK → SLC16A6 |
| (<<) CASP10 → SLC16A6 |
| (<<) CIRH1A → SLC16A6 |
| (<<) DVL3 → SLC16A6 |
| (<<) FZD6 → SLC16A6 |
| (<<) FZD7 → SLC16A6 |
| (<<) ITGB8 → SLC16A6 |
| (<<) ITPR1 → SLC16A6 |
| (<<) KRT6B → SLC16A6 |
| (<<) LRP5 → SLC16A6 |
| (<<) NFIX → SLC16A6 |
| (<<) PTGER4 → SLC16A6 |
| (<<) RHOB → SLC16A6 |
| (<<) TCF7L1 → SLC16A6 |
| Downstream (Children) |
|---|
| SLC16A6 → ACTN4 (>>) |
| SLC16A6 → ASTN2 (>>) |
| SLC16A6 → CHST3 (>>) |
| SLC16A6 → CITED4 (>>) |
| SLC16A6 → DUSP4 (>>) |
| SLC16A6 → DUSP5 (>>) |
| SLC16A6 → EPHB3 (>>) |
| SLC16A6 → FOXO3 (>>) |
| SLC16A6 → GNB5 (>>) |
| SLC16A6 → IL20 (>>) |
| SLC16A6 → KLF11 (>>) |
| SLC16A6 → KYNU (>>) |
| SLC16A6 → MAP3K8 (>>) |
| SLC16A6 → MIA3 (>>) |
| SLC16A6 → MREG (>>) |
| SLC16A6 → PHGDH (>>) |
| SLC16A6 → PKIA (>>) |
| SLC16A6 → RBP1 (>>) |
| SLC16A6 → RPS6KA5 (>>) |
| SLC16A6 → RPS6KB1 (>>) |
| SLC16A6 → SERPINB1 (>>) |
| SLC16A6 → SLC7A5 (>>) |
| SLC16A6 → SMO (>>) |
| SLC16A6 → SOX3 (>>) |
| SLC16A6 → TFF1 (>>) |
| SLC16A6 → TM4SF1 (>>) |
| SLC16A6 → TRERF1 (>>) |
| SLC16A6 → UGDH (>>) |
| SLC16A6 → WWTR1 (>>) |
| SLC16A6 → ZSCAN10 (>>) |
